Acorda patent invalidity appeal for Ampyra denied by court

Acorda Therapeutics (ACOR) holds New Drug Application No. 022250, approved by the U.S. FDA, and pursuant to that approval markets Ampyra. In the FDA’s Orange Book, Acorda has listed, as claiming methods of using Ampyra, four patents that Acorda owns: U.S. Patent No. 8,007,826; No. 8,663,685; No. 8,354,437; and No. 8,440,703. The U.S. Court of Appeals for the Federal Circuit affirm a lower court’s judgment that the asserted Acorda patent claims are invalid. Roxane Laboratories, Mylan Pharmaceuticals (MYL), and Teva Pharmaceuticals (TEVA) have submitted Abbreviated New Drug Applications seeking FDA approval to market generic versions of Ampyra, the Federal Circuit Appeals court ruling noted.
https://thefly.com/landingPageNews.php?id=2788021